Clinical trial
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
NCT06227897
Study timeline
Study start (actual)2024-06-01Date precision: day
Registry last updated2024-12-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lung Cancerunresolved
Interventions
AumolertinibDRUG
Sponsors & collaborators
Sun Yat-sen Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06227897 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.